Biochemical markers in early diagnosis and management of systemic amyloidoses

被引:20
作者
Lavatelli, Francesca [3 ]
Albertini, Riccardo [4 ]
Di Fonzo, Andrea [3 ]
Palladini, Giovanni [3 ,5 ]
Merlini, Giampaolo [1 ,2 ,3 ,4 ,5 ]
机构
[1] Fdn IRCCS Policlin San Matteo, Ctr Studio & Cura Amiloidosi Sistemiche, I-27100 Pavia, Italy
[2] Univ Pavia, I-27100 Pavia, Italy
[3] Fdn IRCCS Policlin San Matteo, Amyloid Res & Treatment Ctr, I-27100 Pavia, Italy
[4] Fdn IRCCS Policlin San Matteo, Clin Chem Lab, I-27100 Pavia, Italy
[5] Univ Pavia, Dept Mol Med, I-27100 Pavia, Italy
关键词
amyloidosis; biomarkers; early diagnosis; monoclonal gammopathies; LIGHT-CHAIN AMYLOIDOSIS; BRAIN NATRIURETIC PEPTIDE; LEUKOCYTE CHEMOTACTIC FACTOR-2; SPECTROMETRY-BASED PROTEOMICS; SUBCUTANEOUS ADIPOSE-TISSUE; STEM-CELL TRANSPLANTATION; SALIVARY-GLAND BIOPSY; CARDIAC TROPONIN-T; AL AMYLOIDOSIS; MONOCLONAL GAMMOPATHY;
D O I
10.1515/cclm-2014-0235
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Systemic amyloid diseases are characterized by widespread protein deposition as amyloid fibrils. Precise diagnostic framing is the prerequisite for a correct management of patients. This complex process is achieved through a series of steps, which include detection of the tissue amyloid deposits, identification of the amyloid type, demonstration of the amyloidogenic precursor, and evaluation of organ dysfunction/damage. Laboratory medicine plays a central role in the diagnosis and management of systemic amyloidoses, through the quantification of the amyloidogenic precursor and evaluation of end-organ damage using biomarkers.
引用
收藏
页码:1517 / 1531
页数:15
相关论文
共 125 条
  • [61] Maurer MS, 2013, J AM COLL CARDIOL, V61
  • [62] Molecular mechanisms of amyloidosis
    Merlini, G
    Bellotti, V
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (06) : 583 - 596
  • [63] Light chain amyloidosis: the heart of the problem
    Merlini, Giampaolo
    Palladini, Giovanni
    [J]. HAEMATOLOGICA, 2013, 98 (10) : 1492 - 1495
  • [64] Differential diagnosis of monoclonal gammopathy of undetermined significance
    Merlini, Giampaolo
    Palladini, Giovanni
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2012, : 595 - 603
  • [65] Systemic light chain amyloidosis: an update for treating physicians
    Merlini, Giampaolo
    Wechalekar, Ashutosh D.
    Palladini, Giovanni
    [J]. BLOOD, 2013, 121 (26) : 5124 - 5130
  • [66] CyBorD: stellar response rates in AL amyloidosis
    Merlini, Giampaolo
    [J]. BLOOD, 2012, 119 (19) : 4343 - 4345
  • [67] Amyloidosis: Pathogenesis and New Therapeutic Options
    Merlini, Giampaolo
    Seldin, David C.
    Gertz, Morie A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (14) : 1924 - 1933
  • [68] Serum-free light chain analysis: works in progress
    Merlini, Giampaolo
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2009, 47 (09) : 1021 - 1022
  • [69] Cardiac amyloidosis: Updates in diagnosis and management
    Mohty, Dania
    Damy, Thibaud
    Cosnay, Pierre
    Echahidi, Najmeddine
    Casset-Senon, Danielle
    Virot, Patrice
    Jaccard, Arnaud
    [J]. ARCHIVES OF CARDIOVASCULAR DISEASES, 2013, 106 (10) : 528 - 540
  • [70] Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis
    Mollee, Peter
    Tate, Jill
    Pretorius, Carel J.
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (12) : 2303 - 2310